Clinical Trials
Harbour BioMed Announces the Phase I Study Results in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
Harbour BioMed
PR-10-24-NI-39Oct 11, 2024
Clinical Trials
StemCyte's HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
StemCyte
PR-09-24-NI-28Oct 07, 2024
Clinical Trials
Soligenix Announces Partnership with Sterling Pharma Solutions
Soligenix, Inc.
PR-09-24-NI-32Oct 07, 2024
Clinical Trials
HyBryte™ expanded treatment results to be presented at the European Organisation for research and treatment of cancer conference
Soligenix, Inc.
PR-10-24-NI-33Oct 07, 2024
Clinical Development
Anixa Biosciences appoints Suyasha Gupta as Senior Director of Clinical Development
Anixa Biosciences
PR-10-24-NI-34Oct 07, 2024
Cell Therapy
Cryoport launches its IntegriCell™ cryopreservation solution with opening of new facility at its Houston Campus
Cryoport
PR-10-24-NI-35Oct 07, 2024
FDA
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
Thryv Therapeutics Inc
PR-09-24-NI-27Oct 03, 2024
FDA
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for the Treatment of Pediatric and Adult Phenylketonuria Patients
PTC Therapeutics, Inc.
PR-09-24-NI-26Oct 03, 2024
Cell Therapy
Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future
Justin Irizarry, CFA
OrganaBio
PAO-09-24-CL-11Sep 30, 2024
Clinical Trail
TALVEY and DARZALEX FASPRO shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-21Sep 27, 2024
Clinical Trails
TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-20Sep 27, 2024
Clinical Trials
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie
PR-09-24-NI-17Sep 26, 2024
CDMO
Wheeler Bio Licenses ATUM’s miFuc Technology to Expand Their Portable CMC Platform Capabilities
Wheeler Bio
PR-09-24-NI-14Sep 24, 2024
Clinical Trail
Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial
Immusoft
PR-09-24-NI-11Sep 23, 2024
Clinical Result
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in Clinical Oncology
Actinium Pharmaceuticals, Inc.
PR-09-24-NI-09Sep 20, 2024
.png?width=3840&quality=75&resize=contain)
CDMO
Serán Bioscience Announces $200 Million Strategic Growth Transaction and Plans for New Commercial Facility
Serán Bioscience
PR-09-24-NI-07Sep 17, 2024
Ophthalmology
The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success
Tracey Roberts, MSHS; Jennifer Christiansen, Ph.D.; Debra Schaumberg, Sc.D., O.D., M.P.H.
PPD, part of Thermo Fisher Scientific
PAO-08-24-CL-05Sep 16, 2024
Female-Centric
Transforming Drug Development through a Female Perspective
Chia Chia Sun; William Freimuth, Ph.D., M.D.
Fab Biopharma
PAO-09-24-CL-03Sep 10, 2024
Breakthrough Results
Breakthrough Results for Jardiance® (Empagliflozin) Confirm Emperor-preserved as First and Only Successful Trial for Heart Failure with Preserved Ejection Fraction
Eli Lilly and Company
PR-M07-21-04Sep 05, 2024
Comparability
Leveraging Risk Assessment for Demonstrating Product Comparability after Manufacturing Process Changes
Pawel Stanczak, Ph.D.; Xuemei Han, Ph.D.; Miguel Carrion
Tanvex CDMO
PAO-07-24-CL-08Aug 26, 2024